News

Also featuring the latest FDA and global drug development pipeline news.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

RLF-100 is an investigational therapy granted an FDA IND this week and looks to treat moderate and severe cases of COVID-19.

A study suggests that both have similar cycle thresholds but the virus lays dormat in an overwhelming majority of asymptomatic patients.

A recent increase in stress cardiomyopathy (Takotsubo Syndrome) could reflect the severe psychosocial pressures of the COVID-19 pandemic.

Dovato can now be used as a complete regimen for treatment of HIV-1 infection to replace an existing ART regimen in adults who are virologically suppressed.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Will screening be based on symptoms alone? How accurate and fast must tests be?

Investigational therapy, RLF-100, is being studied with the goal of preventing progression to respiratory failure.

Earlier research had suggested vitamin D supplementation might lower the risk of tuberculosis, but a new large, randomized trial contradicts those studies.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

This finding suggests large disparities in kids and echoes adult population positive rates.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

The Novavax NVX-CoV2373 vaccine candidate is shown to be well-tolerated and elicited antibody response.

Disease severity was higher among people of color hospitalized with COVID-19, according to a review of chest X-rays.

Two studies will investigate monoclonal antibody-based treatments in both patients with mild disease and those who are hospitalized.

An understanding of what one country saw earlier this year and the prospect of what other countries can do for future openings.

Dr. Patrick Soon-Shiong, CEO of ImmunityBio, initiates a conversation on the nature of the SARS-CoV-2 cytokine storm.

Adam Brufsky, MD, explains the insights years of research into SARS-CoV-1 may hold for SARS-CoV-2.

As the hepatitis C population ages, they experience more age-related mortality causes; direct-acting antiviral therapy may help, a new study finds.

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

A New York City cardiologist talks about the presentation of patients with severe COVID-19 who experienced this condition.

After review of 2 randomized trials, a panel of health care providers and patients see limited benefit for the medication.

The trial will assess a monoclonal antibody based investigational treatment that may prevent COVID-19.

The VIP antiviral therapy shows capability in reducing COVID-19 inflammatory biomarkers, as well as respiratory failure risks.

Collodial stability measures may predict whether a potential antibody-based treatment will work early on in the drug development process.

Medha Munshi, MD, discusses the specific challenges of the quarantine and how she was able to help her patients with diabetes comply with their care.